1-2-dielaidoylphosphatidylethanolamine has been researched along with Adenocarcinoma* in 2 studies
2 other study(ies) available for 1-2-dielaidoylphosphatidylethanolamine and Adenocarcinoma
| Article | Year |
|---|---|
Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy.
The present study was designed to demonstrate the therapeutic efficacy of a novel immunomodulatory oligonucleotide (IMO) for prostate cancer.. We evaluated the effects of the IMO in xenograft (PC-3) and syngeneic (TRAMP C1) models of prostate cancer, and in prostate cancer cells. The IMO was also evaluated in combination with chemotherapy, and the in vitro expression of TLR9 was examined.. The IMO had significant anti-tumor activity in both prostate cancer models and almost complete tumor regression was observed when the IMO was combined with taxotere or gemcitabine. TLR9 mRNA and protein were both expressed in prostate cancer cells. The IMO also induced apoptosis and decreased proliferation and survival of PC-3 cells in vitro in the presence of Lipofectin.. The IMO inhibits prostate cancer growth in vivo and in vitro, and potentiates the effects of conventional chemotherapeutic agents. This is the first report of TLR9 expression in prostate cancer cells. Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Immunologic Factors; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Neoplasm Transplantation; Oligonucleotides; Phosphatidylethanolamines; Prostatic Neoplasms; RNA, Messenger; Taxoids; Toll-Like Receptor 9 | 2006 |
The inhibition of lung cancer cell growth by intracellular immunization with LC-1 ScFv.
A monoclonal antibody, LC-1, recognizing lung cancer associated common antigens was obtained in authors' laboratory. Its single chain Fv fragment (ScFv) named LC-1 ScFv was constructed based on recombinant phage displayed techniques. For expression on cell membrane, LC-1 ScFv was cloned into pDisplay vector, which directed the cloned gene to express as cell membrane bound protein. The resulting plasmid was sequenced and then introduced by the lipofectin method into a lung adenocarcinoma cell line SPC-A-1. G418 resistant cells were obtained by G418 selection. After transfection, LC-1 ScFv expression was observed by Western blot analysis and the expression of cognate antigens was down-regulated as shown in ELISA assay. SPC-A-1-pDisplay-ScFv cells grew in vitro at lower speed than the control intact cells and the cells transfected with vacant vector. Flow cytometry analysis detected a substantial increase in G1 phase and decrease in S phase in population of SPC-A-1-pDisplay-ScFv cells compared to SPC-A-1 and SPC-A-1-pDisplay cells. Semi-quantitative RT-PCR analysis showed that c-myc expression was down-regulated in SPC-A-1-pDisplay-ScFv cells. It seems that the antigens recognized by LC-1 may be in some way involved in a growth stimulating pathway and the antibody blocking of the function of the antigens shut down the pathway and thus down-regulate the expression of c-myc and growth of the cells. Topics: Adenocarcinoma; Amino Acid Sequence; Antibodies, Monoclonal; Base Sequence; Cell Line, Tumor; Cell Membrane; Cloning, Molecular; Gene Expression Regulation, Neoplastic; Humans; Immunization; Immunoglobulin Heavy Chains; Immunoglobulin Light Chains; Immunoglobulin Variable Region; Kinetics; Lung Neoplasms; Molecular Sequence Data; Peptide Library; Phosphatidylethanolamines; Proto-Oncogene Proteins c-myc; Recombinant Proteins; Transfection | 2002 |